RBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh has maintained an 'Outperform' rating on Boston Scientific and raised the price target from $85 to $95.
October 08, 2024 | 6:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its 'Outperform' rating for Boston Scientific and increased the price target to $95, indicating confidence in the company's future performance.
The increase in price target from $85 to $95 by RBC Capital suggests a positive outlook for Boston Scientific, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100